Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries-Reference-Cited by-同舟云学术

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Published:2022-04 Issue: Volume:53 Page:151979
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Egeberg Alexander,Rosenø Nana Aviaaja Lippert,Aagaard David,Lørup Erik Hillo,Nielsen Mia-Louise,Nymand Lea,Kristensen Lars Erik,Thyssen Jacob P.,Thomsen Simon Francis,Cordtz Rene Lindholm,Loft Nikolai^ORCID,Skov Lone,Bryld Lars Erik,Rasmussen Mads Kirchheiner,Højgaard Pil,Kristensen Salome,Dreyer Lene

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference25 articles.

1. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: a Systematic Review and Meta-Analysis;Nast;J. Invest. Dermatol.,2015

2. Biologic fatigue in psoriasis;Levin;J Dermatolog Treat,2014

3. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris;Gniadecki;Br J Dermatol,2015

4. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR);Menter;J Eur Acad Dermatol Venereol,2016

5. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: a Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR);Warren;J. Invest. Dermatol.,2015

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baricitinib: key results of long-term use in rheumatoid arthritis;Modern Rheumatology Journal;2024-08-21

2. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network;Rheumatology International;2024-08-13

3. Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry;Scandinavian Journal of Rheumatology;2024-08-06

4. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

5. Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden;Journal of the European Academy of Dermatology and Venereology;2024-08-02